

[PICTURES IN CLINICAL MEDICINE]

Calcium Channel Blocker-induced Gingival Overgrowth

Hiroki Matsuura^{1,2}, Takashi Fujiwara³ and Shiori Miyashita⁴

Key words: gingival overgrowth, calcium channel blocker

(Intern Med 58: 157, 2019) (DOI: 10.2169/internalmedicine.0852-18)



Picture.

A 69-year-old man was admitted to the hospital with bacterial pneumonia. He had previously been diagnosed with mild hypertension and treated with oral calcium channel blockers for six months. He denied any history of an allergy or exposure to radiation. An oral examination revealed a pale pink, plaque accumulation and gingival inflammation without pain or bleeding (Picture). Based on the clinical history and physical examination findings, the patient was diagnosed with calcium channel blocker-induced gingival overgrowth. Gingival overgrowth is an enlargement of the gum tissue caused by various factors, including inflammatory conditions, hereditary and metabolic disorders, and adverse drug reactions in patients treated with anticonvulsants, immunosuppressants, and calcium channel blockers (1). Despite the popularity and wide use of calcium channel blockers in the treatment of hypertension, this adverse drug reaction is rarely recognized (2). The most effective treatment for drug-induced gingival overgrowth is the withdrawal or substitution of the causative drug.

The authors state that they have no Conflict of Interest (COI).

References

- Bharti V, Bansal C. Drug-induced gingival overgrowth: the nemesis of gingiva unravelled. J Indian Soc Periodontol 17: 182-187, 2013.
- Ono M, Tanaka S, Takeuchi R, et al. Prevalence of amlodipineinduced gingival overgrowth. Int J Oral Med-Sci 9: 96-100, 2010.

The Internal Medicine is an Open Access journal distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. To view the details of this license, please visit (https://creativecommons.org/licenses/ by-nc-nd/4.0/).

¹Department of General Internal Medicine, Kurashiki Central Hospital, Japan, ²Department of General Internal Medicine, Mitoyo General Hospital, Japan, ³Department of Cardiology, Mitoyo General Hospital, Japan and ⁴Department of Dentistry, Mitoyo General Hospital, Japan Received: January 18, 2018; Accepted: June 20, 2018; Advance Publication by J-STAGE: August 24, 2018 Correspondence to Dr. Hiroki Matsuura, superonewex0506@yahoo.co.jp

^{© 2019} The Japanese Society of Internal Medicine. Intern Med 58: 157, 2019